FDA Approves New Treatment Option for Alzheimer’s-Related Agitation

SILVER SPRING, MD — In a milestone for geriatric medicine, the U.S. Food and Drug Administration (FDA) granted approval on April 30, 2026, to Axsome Therapeutics’ AXS-05 (marketed as Auvelity) for the treatment of agitation associated with dementia due to Alzheimer’s disease.

The decision introduces a much-needed second pharmacological option for a condition that affects up to 76% of Alzheimer’s patients. Agitation—characterized by emotional distress, verbal aggression, and physical restlessness—remains one of the most taxing aspects of the disease for both patients and the overstretched network of family caregivers. AXS-05 joins Otsuka’s Rexulti (brexpiprazole), approved in 2023, as the only medications specifically indicated for this purpose.

A Novel Mechanism for Behavioral Health

Unlike traditional antipsychotics often used off-label to manage dementia symptoms, AXS-05 utilizes a distinct dual-action mechanism. It is an oral combination of:

• Dextromethorphan: Commonly known as a cough suppressant, this component modulates NMDA and sigma-1 receptors, which play critical roles in mood and behavioral regulation.

• Bupropion: An antidepressant that serves a dual role here—it provides its own therapeutic effect and, more importantly, inhibits the enzyme that would typically break down dextromethorphan, allowing the latter to reach therapeutic levels in the brain.

“Having a new, neuronally targeted option for agitation is a meaningful step forward,” says Dr. Laura Chen, a geriatric neurologist not involved in the trials. “Agitation is one of the main reasons families seek emergency care or consider nursing home placement. Any therapy that safely reduces these episodes can fundamentally improve quality of life.”

Clinical Evidence: Reducing Relapse and Severity

The FDA’s approval was bolstered by data from a robust clinical program, most notably the ACCORD-2 and ADVANCE-1 Phase 3 trials.

In the ACCORD-2 trial, researchers focused on the drug’s ability to prevent the return of symptoms. The findings were stark: the risk of an agitation relapse was 3.6 times lower for those taking AXS-05 compared to those on a placebo. Specifically, only 8.4% of patients in the treatment group experienced a relapse, versus 28.6% in the placebo group.

The ADVANCE-1 study measured the immediate reduction in symptom severity using the Cohen-Mansfield Agitation Inventory (CMAI), a standard clinical scale. After five weeks, patients on AXS-05 showed a mean reduction of 15.4 points, significantly outperforming the 11.5-point reduction seen in the placebo group. Crucially for this vulnerable population, the study found no evidence of cognitive decline linked to the medication.

Moving Away from “Off-Label” Risks

For decades, clinicians relied on atypical antipsychotics like risperidone to manage agitation. However, these drugs were never FDA-approved for Alzheimer’s-related agitation and carry “black-box” warnings due to an increased risk of stroke and death in elderly patients with dementia-related psychosis.

AXS-05 offers a different safety profile by avoiding the dopamine-blocking pathways associated with the extrapyramidal side effects (such as tremors or muscle stiffness) seen with traditional antipsychotics.

Safety Considerations and Limitations

While the approval is a victory for patient advocacy groups, AXS-05 is not without risks. The most common side effects reported in trials include:

• Dizziness and headache

• Diarrhea

• Somnolence (extreme sleepiness)

Because the formulation contains bupropion, the label includes a boxed warning regarding suicidal thoughts in young adults, though the target demographic for this approval is significantly older. It is also contraindicated for patients with seizure disorders or uncontrolled hypertension.

Experts also stress that AXS-05 is not a “cure-all.” It addresses the behavioral symptoms of Alzheimer’s but does not stop the underlying neurodegeneration. “Real-world evidence will be vital,” notes Dr. Chen. “We still need to see how this drug performs over the long term in frail, elderly patients who are often managing multiple chronic conditions simultaneously.”

Practical Advice for Caregivers

For families navigating the complexities of Alzheimer’s care, this approval shifts the conversation from “managing a nuisance” to treating a clinical symptom. However, medical societies, including the American Psychiatric Association, still recommend a stepwise approach:

1. Non-Pharmacologic First: Attempt environmental modifications, such as reducing noise or maintaining strict daily routines, before starting medication.

2. Consultation: Discuss with a neurologist whether AXS-05 or Rexulti is a better fit based on the patient’s existing medication list (to avoid drug-drug interactions).

3. Monitoring: Caregivers should closely monitor for dizziness or falls, especially during the first few weeks of treatment.

As AXS-05 moves into the domestic market, the focus will likely shift toward insurance coverage and accessibility, ensuring that this new tool in the Alzheimer’s toolkit reaches the families who need it most.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

• U.S. Food and Drug Administration. (2026, April 30). FDA approval of AXS-05 (AUVELITY) for agitation associated with dementia due to Alzheimer’s disease.